Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 526,29 € (+6,59 %). Medianen er 552,37 € (+11,88 %).
| Køb |
49 |
| Behold |
6 |
| Sælg |
1 |
Diskussioner i communityet
- Hallo Community,ich hab bock geroasted zu werden, aus diesem Grund teile ich mi…
P Paddy V i Portfolio Roasts
4 4
Nyheder Til nyhedsfeedet
Vertex aligns growth strategy with kidney medicine
At the Morgan Stanley Healthcare Conference, Vertex presented its shift from a cystic fibrosis focus to a diversified pharma platform, with kidney medicine (Pove for IgA nephropathy, Inaxaplin for APOL1‑related kidney disease) as a central growth axis. Pove has a PDUFA date of Nov. 30 and Vertex reports productive payer discussions in the U.S.; GFR data were withheld to preserve global approval options. Inaxaplin is in the phase‑III AMPLITUDE study with an interim analysis in early 2025. Additional cystic fibrosis and gene‑editing programs continue to provide cash flow and growth potential, while approval, trial results and reimbursement remain risks. » Mere på de.investing.com
Vertex unveils strategy shift beyond cystic fibrosis
At the Cantor Fitzgerald Healthcare Conference, Vertex announced plans to expand its business beyond cystic fibrosis into multiple pillars, focusing on pain, hematology, kidney diseases and rare endocrine disorders following the Crinetics acquisition. CASGEVY and JOURNAVX are expected to generate combined revenue of more than $500m in 2025; JOURNAVX already has 1.6m prescriptions in 2025 and access to 260m insured lives. The PDUFA date for povetacicept in IgA nephropathy is November 30, 2025; inaxaplin is progressing as planned in the phase‑III AMPLITUDE study with interim readouts in early 2027. Vertex emphasized strict acquisition criteria and sees peak sales potential of up to $5bn from Crinetics additions PALSONIFY and Atumelnant. » Mere på de.investing.com
Vertex focuses on kidney therapies as next growth engine
Vertex is shifting to a broader business model and aims to grow beyond cystic fibrosis, particularly in kidney diseases. Key programs include Inaxaplin (AMPLITUDE) for APOL1-mediated diseases with an interim readout in Q1 2027, and Povetacicept for IgA nephropathy (PDUFA 30.11.2024). The integration of Crinetics adds PALSONIFY and Atumelnant to the portfolio; Vertex expects combined peak sales of about $5 billion and cites numerous catalysts over the next 12–24 months. JOURNAVX is showing prescription-side growth, but revenue realization remains temporarily dampened by reimbursement issues. » Mere på de.investing.com
Vertex Pharmaceuticals reaches an all-time high of $555.84
Vertex Pharmaceuticals shares rose to an all-time high of $555.84, close to the 52-week high, with a market capitalization of about $139.72 billion. Over the past year the stock gained 39.95%, reflecting positive market sentiment and investor confidence. Several analysts reaffirmed or raised price targets (RBC $570, BMO $600, Bernstein SocGen $608, Wolfe Research $562) and highlighted potential beyond the cystic fibrosis business. However, an InvestingPro analysis classifies VRTX as overvalued relative to its fair value. » Mere på de.investing.com
Bernstein names Vertex biotech favorite after competing study fails
Bernstein analyst Jeffrey Walch names Vertex a top pick after Sionna released negative topline data for SION-719 in a phase-2a study in cystic fibrosis. The failure of the add-on drug study reduces a key competitive threat to Vertex’s dominant cystic fibrosis business and strengthens the market position of Trikafta/Alyftrek. Walch also sees greater, previously underestimated potential for Vertex beyond the cystic fibrosis indication and expects that Atumelnant could become a meaningful competitor to Crenessity in congenital adrenal hyperplasia. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 3,04 mia. | 15,88 % |
| Bruttofortjeneste | 2,57 mia. | 13,46 % |
| Nettoresultat | 577,03 mio. | 37,47 % |
| EBITDA | 723,41 mio. | 37,40 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 124,06 mia. € |
Antal aktier | 253,54 mio. |
Højeste/laveste i 52 uger | 516,64 € - 374,55 € |
| Udbytte | Nej |
Beta | 0,32 |
P/E (PE Ratio) | 34,39 |
PEG (PEG Ratio) | 3,71 |
K/I (PB Ratio) | 6,53 |
P/S (PS Ratio) | 10,51 |
Virksomhedsprofil
Vertex Pharmaceuticals Incorporated er et bioteknologiselskab, der udvikler og kommercialiserer behandlinger til cystisk fibrose. Selskabet markedsfører SYMDEKO/SYMKEVI, ORKAMBI og KALYDECO til behandling af patienter med cystisk fibrose, som har specifikke mutationer i deres gen for cystisk fibrose transmembrane conductance regulator; samt TRIKAFTA til behandling af patienter med CF, som er 6 år eller ældre, og som har mindst én F508del-mutation. Dets pipeline omfatter VX-864 til behandling af AAT-mangel, som er i klinisk forsøg i fase 2; VX-147 til behandling af APOL1-medieret fokal segmental glomerulosklerose, eller FSGS, og andre alvorlige nyresygdomme, som er i klinisk forsøg i fase 2; VX-880, en behandling af type 1-diabetes, som er i klinisk forsøg i fase 1/2; VX-548, en NaV1.8-hæmmer til behandling af akut, neuropatisk og muskuloskeletal smerte, som er i klinisk forsøg i fase 2; og CTX001 til behandling af svær SCD og TDT, som er i klinisk forsøg i fase 3. Selskabet sælger sine produkter primært til specialapoteker og specialdistributører i USA samt til specialdistributører og detailkæder og hospitaler og klinikker internationalt. Det har samarbejder med Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; og Skyhawk Therapeutics, Inc.; samt Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Tyskland; og X-Chem, Inc. Vertex Pharmaceuticals Incorporated blev grundlagt i 1989 og har hovedkontor i Boston, Massachusetts.
| Navn | Vertex Pharma |
| CEO | Reshma Kewalramani |
| Hjemsted | Boston,
ma USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 05.04.2018 |
| Medarbejdere | 6.400 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | VRTX |
London Stock Exchange | 0QZU.L |
XETRA | VX1.DE |
Frankfurt | VX1.F |
Düsseldorf | VX1.DU |
Hamburg | VX1.HM |
Milan | 1VRTX.MI |
London | 0QZU.L |
SIX | VRTX.SW |
München | VX1.MU |
Wien | VRTX.VI |